Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 2, 2007, Pages 97-106

  Rapkin, Andrea J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

menopause; selective serotonin reuptake inhibitor; serotonin norepinephrine reuptake inhibitor; vasomotor symptoms

Indexed keywords

CITALOPRAM; CLONIDINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; METHYLDOPA; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; PROPRANOLOL; SERTRALINE; VENLAFAXINE; VERALIPRIDE;

ADRENERGIC SYSTEM; ANOREXIA; ANXIETY DISORDER; APPETITE; ARTHRALGIA; BLADDER IRRITATION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DROWSINESS; FATIGUE; GALACTORRHEA; HEADACHE; HOT FLUSH; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; IRRITABILITY; LANGUAGE; LIFE EXPECTANCY; MEMORY DISORDER; MENOPAUSE; MOOD CHANGE; MYALGIA; NAUSEA; NIGHT SWEAT; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; UNITED STATES; VASOMOTOR DISORDER; XEROSTOMIA;

CENTRAL NERVOUS SYSTEM AGENTS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; VASOMOTOR SYSTEM;

EID: 33846928992     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.05.056     Document Type: Review

References (97)

1. United States Life Tables, 2002. Natl Vital Stat Rep 53 (2004) 33-34
2. Health, United States, 2004, with chart book on trends in the health of Americans (2005), National Center for Health Statistics, Hyattsville, MD. http://www.cdc.gov/nchs/data/hus/hus04trend.pdf Available at: http://www.cdc.gov/nchs/data/hus/hus04trend.pdf. Accessed on: October 18
3. Hammond C.B. HEDIS 2000: strategies for successful menopause management. Am J Manag Care 6 suppl (2000) S738-S741
4. United States Bureau of the Census. Projections of the populations of the United States: 1977 to 2050. In: Current population reports. Washington, DC: US Government Printing Office. p. 25-27.
5. Freedman R.R. Physiology of hot flashes. Am J Hum Biol 13 (2001) 453-464
6. Miller R.G., and Ashar B.H. Managing menopause: current therapeutic options for vasomotor symptoms. Adv Stud Med 4 (2004) 484-492
7. Stearns V., Ullmer L., Lopez J.F., Smith Y., Isaacs C., and Hayes D. Hot flushes. Lancet 360 (2002) 1851-1861
8. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 11 (2004) 11-33
9. Moe K.E. Hot flashes and sleep in women. Sleep Med Rev 8 (2004) 487-497
10. Barton D.L., Loprinzi C.L., Novotny P., et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 1 (2003) 47-51
11. Saure A., Planellas J., Poulsen H.K., and Jaszczak P. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. Maturitas 34 (2005) 133-142
12. Kritz-Silverstein D., Goldani V.M., and Barrett-Connor E. Prevalence and clustering of menopausal symptoms in older women by hysterectomy and oophorectomy status. J Womens Health Gend Based Med 9 (2000) 747-755
13. Dennerstein L., Dudley E.C., Hopper J.L., Guthrie J.R., and Burger H.G. A prospective population-based study of menopausal symptoms. Obstet Gynecol 96 (2000) 351-358
14. Feldman B.M., Voda A., and Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 8 (1985) 261-268
15. Guthrie J.R., Dennerstein L., Taffe J.R., and Donnelly V. Health care-seeking for menopausal problems. Climacteric 6 (2003) 112-117
16. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 592 (1990) 52-86
17. Bobula J.D. Vasomotor symptoms and quality of life (QoL) in postmenopausal women. Value Health 6 (2003) 707
18. Brazier J.E., Roberts J., Platts M., and Zoellner Y.F. Estimating a preference-based index for a menopause specific health quality of life questionnaire. Health Qual Life Outcome 3 (2005) 13-22
19. Daly E., Gray A., Barlow D., McPherson K., Roche M., and Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ 307 (1993) 836-840
20. Genazzani A.R., Nicolucci A., Campagnoli C., et al. Assessment of the QoL in Italian menopausal women: comparison between HRT users and non-users. Maturitas 42 (2002) 267-280
21. Rozenberg S., Fellemans C., Kroll M., and Vandromme J. The menopause in Europe. Int J Fertil Women Med 45 (2000) 182-189
22. Schneider H.P. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. Int J Fertil Women Med 42 suppl (1997) 365-375
23. Gambacciani M., Ciaponi M., Cappagli B., et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas 50 (2005) 91-97
24. Shanafelt T.D., Barton D.L., Adjei A.A., and Loprinzi C.L. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 77 (2002) 1207-1218
25. Sikon A., and Thacker H.L. Treatment options for menopausal hot flashes. Cleve Clin J Med 71 (2004) 578-582
26. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 280 (1998) 605-613
27. Hulley S., Furberg C., Barrett-Connor E., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement study follow-up (HERS II). JAMA 288 (2002) 58-66
28. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
29. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 15 (2006) 35-44
30. Klaiber E.L., Vogel W., and Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 84 (2005) 1589-1601
31. Salpeter S. Hormone therapy for younger postmenopausal women: How can we make sense out of the evidence?. Climacteric 8 (2005) 307-310
32. Kessel B., and Kronenberg F. The role of complementary and alternative medicine in management of menopausal symptoms. Endocrinol Metab Clin North Am 33 (2004) 717-739
33. Robertson J.F. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 30 (2004) 695-706
34. Swegle J.M., and Kelly M.W. Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother 38 (2004) 874-881
35. Hutton J.D., Jacobs H.S., Murray M.A., and James V.H. Relation between plasma oestrone and oestradiol and climacteric symptoms. Lancet 1 (1978) 678-681
36. Freedman R.R. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 23 (2005) 117-125
37. Freedman R.R., Norton D., Woodward S., and Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 80 (1995) 2354-2358
38. Freedman R.R. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 70 (1998) 332-337
39. Deecher D.C., Leventhal L., Numan S., et al. Desvenlafaxine alleviates vasomotor instability in two rodent models of hot flush (2005), Women's Health Research Institute, Wyeth Research, Collegeville (PA)
40. Bruck K., and Hinckel P. Thermoregulatory noradrenergic and serotonergic pathways to hypothalamic units. J Physiol 304 (1980) 193-202
41. Maas J. MHPG: basic mechanisms and psychopathology (1983), Academic Press, New York
42. Freedman R.R., Woodward S., and Sabharwal S.C. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 76 (1990) 573-578
43. Berendsen H.H. The role of serotonin in hot flushes. Maturitas 36 (2000) 155-164
44. Sipe K., Leventhal L., Burroughs K., Cosmi S., Johnston G.H., and Deecher D.C. Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res 1028 (2004) 191-202
45. Slopien R., Meczekalski B., and Warenik-Szymankiewicz A. Relationship between climacteric symptoms and serum serotonin levels in postmenopausal women. Climacteric 6 (2003) 53-57
46. Vliet E.L., and Davis V.L. New perspectives on the relationship of hormone changes to affective disorders in the perimenopause. NAACOGS Clin Issue Perinat Womens Health Nurs 2 (1991) 453-471
47. Rubinow D.R., Schmidt P.J., and Roca C.A. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatr 44 (1998) 839-850
48. Portas C.M., Bjorvatn B., and Ursin R. Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Prog Neurobiol 60 (2000) 13-35
49. Stearns V., Isaacs C., Rowland J., et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 11 (2000) 17-22
50. Henderson V.W., Klein B.E.K., and Resnick S.M. Menopause and disorders of neurologic function, mental health, and the eye. In: Wenger N. (Ed). International position paper on women's health and menopause: a comprehensive approach (2002), National Institutes of Health, Bethesda (MD) 251-270
51. Freedman R.R., and Roehrs T.A. Lack of sleep disturbance from menopausal hot flashes. Fertil Steril 82 (2004) 138-144
52. Loprinzi C.L., Flynn P.J., Carpenter L.A., et al. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med 8 (2005) 924-930
53. Loprinzi C.L., Sloan J.A., Perez E.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20 (2002) 1578-1583
54. Loprinzi C.L., Barton D.L., Carpenter L.A., et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 79 (2004) 1247-1251
55. Stearns V., Beebe K.L., Iyengar M., and Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289 (2003) 2827-2834
56. Stearns V., Slack R., Greep N., et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 23 (2005) 6919-6930
57. Weitzner M.A., Moncello J., Jacobsen P.B., and Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 23 (2002) 337-345
58. Nagata H., Nozaki M., and Nakano H. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res 31 (2005) 107-114
59. Suvanto-Luukkonen E., Koivunen R., Sundstrom H., et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 12 (2005) 18-26
60. Nemeroff C.B., and Owens M.J. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr 9 suppl (2004) 23-31
61. Bachmann G.A. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 50 (2005) 155-165
62. Masand P.S., and Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatr 7 (1999) 69-84
63. Loprinzi C.L., Pisansky T.M., Fonseca R., et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16 (1998) 2377-2381
64. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356 (2000) 2059-2063
65. Barton D., LaVasseur B., Loprinzi C., Novotny P., Wilwerding M.B., and Sloan J. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 29 (2002) 33-40
66. Biglia N., Torta R., Roagna R., et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 52 (2005) 78-85
67. Evans M.L., Pritts E., Vittinghoff E., McClish K., Morgan K.S., and Jaffe R.B. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 105 (2005) 161-166
68. Quella S.K., Loprinzi C.L., Sloan J., et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 162 (1999) 98-102
69. Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatr 56 suppl (1995) 12-21
70. Guttuso Jr. T., Kurlan R., McDermott M.P., and Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 101 (2003) 337-345
71. Pandya K.J., Morrow G.R., Roscoe J.A., et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 366 (2005) 818-824
72. Stearns V., and Loprinzi C.L. New therapeutic approaches for hot flashes in women. J Support Oncol 1 (2003) 11-21
73. Clayden J.R., Bell J.W., and Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. BMJ 1 (1974) 409-412
74. Nagamani M., Kelver M.E., and Smith E.R. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 156 (1987) 561-565
75. Salmi T., and Punnonen R. Clonidine in the treatment of menopausal symptoms. Int J Gynaecol Obstet 16 (1979) 422-426
76. Wren B.G., and Brown L.B. A double-blind trial with clonidine and a placebo to treat hot flushes. Med J Aust 144 (1986) 369-370
77. Goldberg R.M., Loprinzi C.L., O'Fallon J.R., et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12 (1994) 155-158
78. Laufer L.R., Erlik Y., Meldrum D.R., and Judd H.L. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 60 (1982) 583-586
79. Pandya K.J., Raubertas R.F., Flynn P.J., et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 132 (2000) 788-793
80. Fujimura A., Ebihara A., Ohashi K., et al. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects. J Clin Pharmacol 34 (1994) 260-265
81. Nesheim B.I., and Saetre T. Reduction of menopausal hot flushes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol 20 (1981) 413-416
82. Andersen O., Engebretsen T., Solberg V.M., and Orbo A. Alpha-methyldopa for climacteric hot flushes: a double-blind, randomized, cross-over study. Acta Obstet Gynecol Scand 65 (1986) 405-409
83. Morgante G., Farina M., Cianci A., et al. Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women. Gynecol Endocrinol 18 (2004) 194-198
84. Vercellini P., Sacerdote P., Trespidi L., Manfredi B., Panerai A.E., and Crosignani P.G. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril 62 (1994) 938-942
85. Melis G.B., Gambacciani M., Cagnacci A., Paoletti A.M., Mais V., and Fioretti P. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 72 (1988) 688-692
86. David A., Don R., Tajchner G., and Weissglas L. Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 158 (1988) 1107-1115
87. Vercellini P., Vendola N., Colombo A., Passadore C., Trespidi L., and Crosignani P.G. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest 34 (1992) 102-104
88. Wesel S., Bourguignon R.P., and Bosuma W.B. Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes. Curr Med Res Opin 8 (1984) 696-700
89. Zichella L., Falaschi P., Fioretti P., et al. Effects of different dopamine agonists and antagonists on post-menopausal hot flushes. Maturitas 8 (1986) 229-237
90. Perez D.G., Loprinzi C.L., Barton D.L., et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2 (2004) 50-56
91. Tarim E., Bagis T., Kilicdag E., Erkanli S., Aslan E., and Kuscu E. Moclobemide in the treatment of hot flashes in postmenopausal women. Adv Ther 19 (2002) 258-265
92. Coope J., Williams S., and Patterson J.S. A study of the effectiveness of propranolol in menopausal hot flushes. BJOG 85 (1978) 472-475
93. Loprinzi C.L., Stearns V., and Barton D. Centrally active nonhormonal hot flash therapies. Am J Med 118 suppl (2005) 118-123
94. Plouffe Jr. L., Trott E.A., Largoza M., and Hansen K.A. An open trial of sertraline for menopausal hot flushes: potential involvement of serotonin in vasomotor instability. Del Med J 69 (1997) 481-482
95. Pandya K.J., Thummala A.R., Griggs J.J., et al. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Res Treat 83 (2004) 87-89
96. Loprinzi L., Barton D.L., Sloan J.A., et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 77 (2002) 1159-1163
97. Lindsay R., and Hart D.M. Failure of response of menopausal vasomotor symptoms to clonidine. Maturitas 1 (1978) 21-25